Rapport Therapeutics
RAPP
23.16
-0.43
-1.82%
Rapport Therapeutics
US · RAPP
#2970 by market cap
Listed 2024
23.16
-0.43
-1.82%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
CrossFirst Bankshares | 4: Statement of changes in beneficial ownership of securities-Officer Rapp W. RandallSEC · 2025/2/27
-
Rating change
Goldman Sachs Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $68Market Newswire · 2026/10/22
-
Rating change
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $50 to $91Market Newswire · 2026/10/21
-
Rating change
Analysts' Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)TipRanks · 2026/10/21
-
Rating change
Guggenheim Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $70Market Newswire · 2026/10/22
-
Rating change
Rapport Therapeutics, Inc. (RAPP) Gets a Buy From Goldman SachsTipRanks · 2026/10/22
-
H.C. Wainwright Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Cuts Target Price to $63Market Newswire · 2026/11/6
-
Company notice
CrossFirst Bankshares(Delisted) | 4: Statement of changes in beneficial ownership of securities-Officer Rapp W. RandallSEC · 2025/3/5
-
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $47Market Newswire · 2026/11/6
-
Company notice
The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.SEC · 2026/1/27
-
Rating change
Wells Fargo Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)TipRanks · 2026/10/18
-
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $82Market Newswire · 2026/11/12
-
Company notice
The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.SEC · 2026/2/11
-
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Cuts Target Price to $47Market Newswire · 2026/11/5
-
Rating change
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/10/22
-
UBS Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $64Market Newswire · 2026/11/6
-
Rating change
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Raises Target Price to $82Market Newswire · 2026/10/22
-
Rating change
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $51Market Newswire · 2026/10/20
-
Company notice
The Bank of Princeton | 4: Statement of changes in beneficial ownership of securities-Officer Rapp George S.SEC · 2026/1/23
-
Rating change
Wolfe Research Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $50Market Newswire · 2026/10/15
-
Rating change
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and The Estée Lauder Companies (EL)TipRanks · 2026/9/24
-
Rating change
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $66 to $66Market Newswire · 2026/9/24
-
Rating change
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $66 to $75Market Newswire · 2026/9/23
-
Rating change
BTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)TipRanks · 2026/10/2
-
Rating change
BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $75Market Newswire · 2026/10/2
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Rapport Therapeutics discussion 0 comments